Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis

What Was Tested

The paper reports a study of Vasopressin and Desmopressin in the context of multiple sclerosis, published as a randomized controlled trial.

Who Took Part

The study group was 11 men.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Twenty-two women and 11 men, under 65 years of age, with clinically definite multiple sclerosis and nocturnal frequency +/- enuresis were entered into the study.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the men nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

Some men received a placebo instead of Vasopressin, giving a reference point.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Deamino Arginine Vasopressin, Enuresis, Multiple Sclerosis and Urination Disorders.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in 11 men in people with multiple sclerosis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1994 (British journal of urology), a journal based in England.

More context: the Vasopressin compound page and the Desmopressin compound page, Multiple sclerosis research.